MCL1 and B-cell chronic lymphocytic leukemia: This phenomenon supports the observation that CLL cells exhibit increased sensitivity to CB-839 in combination with AZD-5991, the MCL-1 inhibitor; the combination eliminates MCL-1 protein’s protective effect.